Company intelligence / Profile preview

Cellatoz Therapeutics, Inc.

Seongnam-si, Gyeonggi-do, South Koreacellatozrx.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

The company has initiated a Phase 1 clinical trial in South Korea for CLZ‑2002, a Schwann-cell-based regenerative therapy targeting Charcot-Marie-Tooth disease. Preclinical studies have demonstrated safety and efficacy in animal models. Additional programs are in preclinical or discovery stages targeting musculoskeletal disorders and oncology.[6][8]

Therapeutic areas: RheumatologyEndocrinologyOtherOncologyNeurology
Modalities: Cell therapyMesenchymal stem cell therapyNK cell therapy
Industry: Biotech

Drug pipeline

2 assets

CLZ-2002

1 more asset in the full pipeline.

Request access →

Partnerships

Ewha Womans University Medical Center"[1]

Beyond the preview

Go deeper on Cellatoz Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellatoz Therapeutics, Inc..

Explore the full profile